Auspex Pharmaceuticals Garners $25,000,000 Series D Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=72be8886-b425-4b54-b4a3-2af05532c9c6&Preview=1 -
Date
11/9/2012 -
Company Name
Auspex Pharmaceuticals -
Mailing Address
3366 North Torrey Pines Court La Jolla, CA 92037 -
Company Description
Auspex Pharmaceuticals is a developer of next-generation medicines with improved safety and performance and a pioneer in the targeted application of deuterium chemistry to clinically validated drugs. For more than five years the company has worked to apply its targeted deuteration strategy to drug molecules across multiple therapeutic areas, secure a proprietary position on several hundred compounds and initiate development on multiple clinical candidates. -
Website
http://www.auspexpharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$25,000,000 -
Transaction Round
Series D -
Proceeds Purposes
Auspex will use the funds to advance the development of its portfolio of drug molecules, particularly the Phase 3 development of its lead molecule, SD-809, expected to begin in the first half of 2013. -
M&A Terms
-
Venture Investor
Panorama Capital -
Venture Investor
Thomas, McNerny & Partners -
Venture Investor
CMEA Capital
